Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he
Always a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes to cancer immunotherapy, but a new R&D alliance with Dutch biotech Merus is further evidenc
